Investor Relations

NYSE: NVRO

Price

78.30 +0.90 ( +1.16% ) 4:02 1/19/18 Pricing delayed 20 minutes

Volume 335,215

Recent News

See All
January 12, 2018 Nevro to Highlight Body of Clinical Evidence Supporting Expanded Use and Potential New Indications of Company's Senza Spinal Cord Stimulation Systems Delivering HF10™ Therapy at NANS Annual Meeting
Non-Opioid Treatment Option Offers Profound, Paresthesia-Free Pain Relief for Growing Numbers of Patients Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of HF10 ™ therapy for patients with chronic pain at the 21 st Annual Meeting of the North American Neuromodulation Society (NANS) taking place through January 14 in Las Vegas . "Our large and growing body of clinical evidence supports the use of HF10 therapy for patients suffering from debilitating chronic pain and looking for alternatives to opioids," said Rami Elghandour, President and CEO of Nevro. "With a number of studies initiated in a variety of pain areas and indications, we are uniquely positioned to deliver on the promise of neuromodulation by applying our best-in-class therapy to treat a broad array of challenging disease states.  In today's environment,...
January 8, 2018 Nevro Receives FDA Approval for Senza II™ Spinal Cord Stimulation System Delivering HF10™ Therapy
Superior, Non-Opioid Therapy Now Delivered in a Smaller and More Refined IPG Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has received FDA approval for its next-generation Senza II Spinal Cord Stimulation (SCS) System delivering HF10 therapy. The Senza II system offers the superior outcomes and clinical advantages of HF10 therapy through a smaller and more refined footprint while maintaining the performance and durability of the current Implantable Pulse Generator (IPG). "My colleagues and I are excited about the approval of the Senza II SCS system," said Dr. Tom Simopoulos, Director of Pain Medicine and Co-Director of the Spine Center at the Beth Israel Deaconess Medical Center (an affiliate of the Harvard Medical School) in Boston, MA. "The reduced size and optimized design of the Senza II IPG allow for greater patient comfort and placement options. Most...
January 8, 2018 Nevro Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2017 Revenue
Company Provides Worldwide Revenue Guidance for Full Year 2018 Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced its preliminary unaudited revenue for the fourth quarter and year ended December 31, 2017 . The company announced that preliminary unaudited fourth quarter worldwide revenue is expected to be in the range of $97.4 to $97.9 million, compared to $70.5 million in the fourth quarter of 2016. Preliminary unaudited U.S. revenue for the fourth quarter of 2017 is expected to be in the range of $80.7 to $81.0 million .  Preliminary unaudited international revenue for the fourth quarter of 2017 is expected to be in the range of $16.7 to $16.9 million . Nevro's preliminary unaudited full year 2017 revenue is expected to be in the range of $326.1 to $326.6 million compared to $228.5 million in 2016. Worldwide Revenue Guidance for Full Year 2018 The company expects worldwide...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza System is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.